Why did ORMP's operating expenses drop sharply in Q2 2024?

The operating expenses of Oramed Pharmaceuticals Inc. (ORMP) for Q2 2024 are not available. However, we can analyze the earnings estimates and other financial metrics to understand the company's financial health and any potential factors affecting its operating expenses. 1. **Earnings Estimates and Performance**: Oramed Pharmaceuticals is forecasted to earn $0.04 per share in Q2 2024, which is a positive indicator as it beats the consensus estimate of ($0.12) by $0.04. This suggests that the company is performing well and may indicate a reduction in operating expenses as the company is able to generate earnings despite the lack of revenue reported in the quarter. 2. **Analyst Ratings and Forecasts**: The stock has been given a "Neutral" rating by HC Wainwright, which may suggest a cautious outlook from the analysts. Additionally, the forecasted earnings per share for Q3 2024 is also $0.04, which is a slight increase from the previous quarter's earnings. This could imply that the company is managing its expenses effectively to maintain profitability. 3. **Institutional Activity**: There has been some institutional investment activity, with Barclays PLC and Algert Global LLC increasing their positions in the company. This could reflect confidence from institutional investors in the company's potential, which may have an indirect impact on operating expenses as these investors may influence the company's strategic decisions. In conclusion, while the exact reasons for the drop in operating expenses are not available, the company's ability to generate earnings, analyst forecasts, and institutional investment activity suggest that Oramed Pharmaceuticals is managing its expenses effectively. Further details on the company's expense management strategies and specific expense items would be needed to provide a more detailed analysis.